Pinatuzumab vedotin

Pinatuzumab vedotin
Monoclonal antibody
Type?
SourceHumanized (from mouse)
TargetCD22
Clinical data
Other namesDCDT2980S, FCU2703
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
Chemical and physical data
FormulaC6748H10377N1773O2083S44
Molar mass151081.21 g·mol−1

Pinatuzumab vedotin (INN;[1] development codes DCDT2980S and FCU2703) is a monoclonal antibody designed for the treatment of B-cell malignancies.[2]

This drug was developed by Genentech/Roche.

References

  1. ^ World Health Organization (2012). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 108" (PDF). WHO Drug Information. 26 (4).
  2. ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Pinatuzumab Vedotin, American Medical Association.
This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.